- Home
- ETON vs PACB Comparison
ETON vs PACB Comparison
Compare ETON & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- PACB
- Stock Information
- Founded
- ETON 2017
- PACB 2000
- Country
- ETON United States
- PACB United States
- Employees
- ETON N/A
- PACB N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- PACB Biotechnology: Laboratory Analytical Instruments
- Sector
- ETON Health Care
- PACB Industrials
- Exchange
- ETON Nasdaq
- PACB Nasdaq
- Market Cap
- ETON 388.3M
- PACB 462.1M
- IPO Year
- ETON 2018
- PACB 2010
- Fundamental
- Price
- ETON $14.39
- PACB $1.39
- Analyst Decision
- ETON Strong Buy
- PACB Buy
- Analyst Count
- ETON 3
- PACB 9
- Target Price
- ETON $29.67
- PACB $2.06
- AVG Volume (30 Days)
- ETON 420.1K
- PACB 7.3M
- Earning Date
- ETON 08-07-2025
- PACB 08-07-2025
- Dividend Yield
- ETON N/A
- PACB N/A
- EPS Growth
- ETON N/A
- PACB N/A
- EPS
- ETON N/A
- PACB N/A
- Revenue
- ETON $48,327,000.00
- PACB $152,357,000.00
- Revenue This Year
- ETON $101.12
- PACB $3.33
- Revenue Next Year
- ETON $45.71
- PACB $17.88
- P/E Ratio
- ETON N/A
- PACB N/A
- Revenue Growth
- ETON 40.88
- PACB N/A
- 52 Week Low
- ETON $3.25
- PACB $0.85
- 52 Week High
- ETON $21.48
- PACB $2.72
- Technical
- Relative Strength Index (RSI)
- ETON 45.76
- PACB 47.77
- Support Level
- ETON $13.78
- PACB $1.50
- Resistance Level
- ETON $15.73
- PACB $1.69
- Average True Range (ATR)
- ETON 0.75
- PACB 0.14
- MACD
- ETON -0.01
- PACB -0.03
- Stochastic Oscillator
- ETON 31.98
- PACB 21.28
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.